Latest News and Press Releases

NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...

NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...

NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial...

Lantheus Holdings, Inc. to Acquire Progenics to Form an Innovative Commercial Life Sciences Company with a Diversified Portfolio of Precision Diagnostics and Radiopharmaceutical TherapeuticsAZEDRA...

Warns Shareholders to Ignore Earlier and Illusory Consent Cutoff Set by Velan Urges Shareholders to Review the S-4 Filing that Will be Made the Week of November 11 about the Value Maximizing Lantheus...

November 17 is the Only Deadline for Velan’s Consent Solicitation Reminds Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17 ...

Notifies Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17 Shareholders Should Ignore Any Earlier Dates to Deliver Consents...

ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders to Protect the Value of...

Flags Velan’s Knowledge of Lantheus Transaction Weeks Before It Was Made Public Raises Significant Concerns About Velan’s Questionable Securities Trading, Governance and Ethical Practices Asks...

Calls Out Velan’s Pattern of Disregard for Good Corporate Governance and Business Ethics Reminds Shareholders to Sign and Return Progenics’ WHITE Consent Revocation Card NEW YORK, Oct. 21, 2019 ...